Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 2:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 1,742 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Formulation #2 Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine Candidate in Healthy Adults (19-49 Years)

NCT06698198
View directory record Official record
Conditions
Pneumococcal Immunization
Interventions
Pneumococcal Conjugate Vaccine, Prevnar 13®
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
19 Years to 49 Years
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Metairie, Louisiana • Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 31, 2026, 2:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Comparative Bioavailability of BMS-986278 in Healthy Participants

NCT06715683
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986278 Batched method, Dose A, BMS-986278 Batched method, Dose B, BMS-986278 Continuous method
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 31, 2026, 2:11 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects

NCT01668537
View directory record Official record
Conditions
Smallpox
Interventions
LF formulation of IMVAMUNE®, FD formulation of IMVAMUNE®
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 55 Years
Enrollment
651 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
3
States / cities
South Miami, Florida • Lenexa, Kansas • Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 12, 2020 · Synced Oct 31, 2026, 2:11 PM EDT
Completed Phase 2 Interventional Results available

Evaluate Weight Gain Using 2 Different Formulations of Megestrol Acetate Oral Suspension for AIDS-related Weight Loss

NCT00637572
View directory record Official record
Conditions
HIV Infections, Cachexia, Anorexia, AIDS Wasting Syndrome, HIV Wasting Syndrome
Interventions
Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL, Megestrol acetate oral suspension 40 mg/mL
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Oct 31, 2026, 2:11 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD

NCT04542057
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Ensifentrine, Placebo
Drug
Lead sponsor
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Industry
Eligibility
40 Years to 80 Years
Enrollment
790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
77
States / cities
Alabaster, Alabama • Andalusia, Alabama • Jasper, Alabama + 60 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 31, 2026, 2:11 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

V160 2-Dose and 3-Dose Regimens in Healthy Cytomegalovirus (CMV) Seronegative Females (V160-002)

NCT03486834
View directory record Official record
Conditions
Cytomegalovirus (CMV) Infections
Interventions
V160, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years to 35 Years · Female only
Enrollment
2,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
54
States / cities
Birmingham, Alabama • Chandler, Arizona • Rialto, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Oct 31, 2026, 2:11 PM EDT
Terminated Phase 2 Interventional Results available

Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants

NCT03107871
View directory record Official record
Conditions
Cmv Congenital, CMV, Congenital Cmv, SNHL, Sensorineural Hearing Loss
Interventions
Valganciclovir, Simple Syrup
Drug
Lead sponsor
Albert Park
Other
Eligibility
1 Month to 12 Months
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
30
States / cities
Palo Alto, California • San Diego, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 31, 2026, 2:11 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess an Enteric Microgranule Formulation of Adrulipase in Patients With Cystic Fibrosis

NCT05719311
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency, Cystic Fibrosis
Interventions
adrulipase
Drug
Lead sponsor
Entero Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
3
States / cities
Orlando, Florida • Northfield, Illinois • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 31, 2026, 2:11 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV

NCT01602822
View directory record Official record
Conditions
HIV
Interventions
Tenofovir DF and Emtricitabine; Ritonavir-boosted Atazanavir
Drug
Lead sponsor
Kenneth H. Mayer, MD
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Oct 31, 2026, 2:11 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults

NCT03483961
View directory record Official record
Conditions
Chikungunya Virus Infection
Interventions
CHIKV VLP/unadjuvanted, CHIKV VLP/adjuvanted, Placebo
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 45 Years
Enrollment
445 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
3
States / cities
Lenexa, Kansas • Kansas City, Missouri • West Jordan, Utah
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 31, 2026, 2:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pilot Study to Evaluate the PK Profile of PrimeC-ER Tablets in Healthy Adult Subjects

NCT05232461
View directory record Official record
Conditions
Pharmacokinetics
Interventions
PrimeC-ER 748 mg, Ciprofloxacin 750 MG, Celecoxib 200mg
Drug
Lead sponsor
NeuroSense Therapeutics Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Oct 31, 2026, 2:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sun Protection Factor - Assay

NCT02779842
View directory record Official record
Conditions
Sunscreening Agent
Interventions
Coppertone (BAY 987517)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Union, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Oct 31, 2026, 2:11 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Comparative Pharmacokinetics and Food-Effect Bioavailability of Lubiprostone Sprinkle in Healthy Volunteers

NCT03010631
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Cohort 1: Lubiprostone Capsule, Fasted, Cohort 1: Lubiprostone Sprinkle Formulation, Fasted, Cohort 2: Lubiprostone Sprinkle Formulation, Fed, Cohort 2: Lubiprostone Sprinkle Formulation, Fasted
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 31, 2026, 2:11 PM EDT
Recruiting Phase 2 Interventional

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

NCT03907475
View directory record Official record
Conditions
Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Capecitabine, Carboplatin, Computed Tomography, Durvalumab, Echocardiography Test, Gemcitabine Hydrochloride, Nab-paclitaxel, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 31, 2026, 2:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine

NCT03078556
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Dolutegravir, Lamivudine, Dolutegravir + Lamivudine FDC Formulation 1, Dolutegravir + Lamivudine FDC Formulation 2
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Oct 31, 2026, 2:11 PM EDT
Completed Phase 2 Interventional

Study to Evaluate Safety/Efficacy of a Single Preop Dose of AYX1 Injection to Treat Pain After Knee Replacement Surgery

NCT02807428
View directory record Official record
Conditions
Post-surgical Pain
Interventions
AYX1 Injection 660 mg/6 mL, Placebo Injection 6 mL
Drug
Lead sponsor
Adynxx, Inc.
Industry
Eligibility
40 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
9
States / cities
Birmingham, Alabama • Sheffield, Alabama • Phoenix, Arizona + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 31, 2026, 2:11 PM EDT
Recruiting Phase 2 Interventional

A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)

NCT07116031
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Belumosudil
Drug
Lead sponsor
Sanofi
Industry
Eligibility
1 Year to 18 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
7
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 31, 2026, 2:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Tear Film Break-up Time After Instillation of Artificial Tears

NCT00681265
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
glycerin, polyethylene glycol 400/propylene glycol
Drug
Lead sponsor
Calm Water Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 26, 2012 · Synced Oct 31, 2026, 2:11 PM EDT
Completed Phase 3 Interventional

Evaluation of an Anti-HIV Drug Combination That Includes a Coated Form of Didanosine (ddI EC) Compared to a Typical Anti-HIV Drug Regimen

NCT00002429
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine/Zidovudine, Nelfinavir mesylate, Stavudine, Didanosine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 4, 2011 · Synced Oct 31, 2026, 2:11 PM EDT
Terminated Phase 4 Interventional

Tandem OnabotulinumtoxinA Galcanezumab Emerging Therapeutic Headache Elimination Research Study

NCT05492695
View directory record Official record
Conditions
Migraine
Interventions
Galcanezumab, Placebo
Drug · Other
Lead sponsor
Diamond Headache Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 31, 2026, 2:11 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma

NCT01383928
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Ixazomib, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
20
States / cities
Berkeley, California • Duarte, California • Stanford, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Oct 31, 2026, 2:11 PM EDT
Completed Phase 3 Interventional Results available

Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation

NCT01993875
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
11
States / cities
Anniston, Alabama • Anaheim, California • DeLand, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Oct 31, 2026, 2:11 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma

NCT04768881
View directory record Official record
Conditions
Locally Advanced Unresectable or Metastatic Melanoma
Interventions
Selinexor, Pembrolizumab
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
13
States / cities
Los Angeles, California • Pasadena, California • Plantation, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Oct 31, 2026, 2:11 PM EDT
Recruiting Phase 1Phase 2 Interventional

SMP-3124LP in Adults With Advanced Solid Tumors

NCT06526819
View directory record Official record
Conditions
Solid Tumor
Interventions
SMP3124LP
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 31, 2026, 2:11 PM EDT